SpringWorks Therapeutics (SWTX) News Today $58.90 -1.04 (-1.73%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period SpringWorks Therapeutics (NASDAQ:SWTX) Sets New 1-Year High - Time to Buy?SpringWorks Therapeutics (NASDAQ:SWTX) Hits New 1-Year High - What's Next?February 21 at 11:51 AM | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch Sells 400 SharesSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) Director Daniel Lynch sold 400 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $60.00, for a total transaction of $24,000.00. Following the completion of the sale, the director now owns 130,544 shares in the company, valued at $7,832,640. The trade was a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.February 20 at 5:11 PM | marketbeat.comInsider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells 10,672 Shares of StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) CEO Saqib Islam sold 10,672 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $59.92, for a total value of $639,466.24. Following the transaction, the chief executive officer now owns 1,063,953 shares of the company's stock, valued at approximately $63,752,063.76. The trade was a 0.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.February 20 at 5:11 PM | marketbeat.comSpringWorks Therapeutics reports FY24 EPS ($3.48), consensus ($3.16)February 20 at 8:38 AM | markets.businessinsider.comSpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors ExpectFebruary 20 at 8:38 AM | msn.comWhy SpringWorks Therapeutics, Inc. (SWTX) is the Best Performing Healthcare Stock So Far in 2025February 20 at 8:38 AM | msn.comSpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business UpdatesFebruary 20 at 6:30 AM | globenewswire.comDaniel Lynch Sells 400 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) StockFebruary 20 at 5:41 AM | insidertrades.comSpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Down - What's Next?SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Down - Time to Sell?February 19 at 11:38 PM | marketbeat.comSpringWorks, Jennifer Fisher team to increase understanding of desmoid tumorsFebruary 19 at 11:53 AM | markets.businessinsider.comSpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes OverFebruary 19 at 8:00 AM | prnewswire.comHere's What Could Help SpringWorks Therapeutics (SWTX) Maintain Its Recent Price StrengthFebruary 17, 2025 | msn.comOnco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLIâ„¢ (mirdametinib), Manufactured By SpringWorks TherapeuticsFebruary 17, 2025 | globenewswire.comWedbush Analysts Lift Earnings Estimates for SWTXSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Wedbush upped their Q2 2025 earnings estimates for SpringWorks Therapeutics in a research report issued to clients and investors on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the company will post earningFebruary 17, 2025 | marketbeat.comHC Wainwright Has Negative Outlook for SWTX FY2024 EarningsSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now expects that the company willFebruary 17, 2025 | marketbeat.comSpringWorks Therapeutics' (SWTX) Buy Rating Reaffirmed at HC WainwrightFebruary 15, 2025 | americanbankingnews.comSpringWorks Therapeutics (SWTX) to Release Earnings on ThursdaySpringWorks Therapeutics (NASDAQ:SWTX) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=660715)February 15, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Buy" from AnalystsSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) has been assigned a consensus rating of "Buy" from the six research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price amoFebruary 14, 2025 | marketbeat.comSpringWorks therapeutics director Daniel Lynch sells $9.53 million in stockFebruary 13, 2025 | msn.comSpringWorks Therapeutics price target raised to $87 from $65 at BofAFebruary 13, 2025 | markets.businessinsider.comFiera Capital Corp Reduces Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Fiera Capital Corp lessened its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,219,189 shares of the company's stock afteFebruary 13, 2025 | marketbeat.comInsider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Sells 30,000 Shares of StockFebruary 13, 2025 | insidertrades.comSpringWorks Therapeutics price target raised to $66 from $63 at TD CowenFebruary 13, 2025 | markets.businessinsider.comRep. Gilbert Ray Cisneros, Jr. Buys SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) StockRepresentative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in SpringWorks Therapeutics stock on January 29th. TheFebruary 13, 2025 | marketbeat.comSpringworks Therapeutics CEO sells $2.56 million in stockFebruary 12, 2025 | msn.comSpringWorks Therapeutics CEO sells $2.56M in common stockFebruary 12, 2025 | markets.businessinsider.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Sells $1,593,900.00 in StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) COO Badreddin Edris sold 30,000 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $53.13, for a total value of $1,593,900.00. Following the sale, the chief operating officer now owns 189,712 shares in the company, valued at approximately $10,079,398.56. The trade was a 13.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.February 12, 2025 | marketbeat.comDaniel Pichl Sells 29,750 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) insider Daniel Pichl sold 29,750 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $54.36, for a total transaction of $1,617,210.00. Following the completion of the transaction, the insider now directly owns 50,762 shares of the company's stock, valued at $2,759,422.32. This represents a 36.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 12, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells $2,558,400.00 in StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) CEO Saqib Islam sold 48,000 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $53.30, for a total value of $2,558,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,002,502 shares of the company's stock, valued at approximately $53,433,356.60. This represents a 4.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.February 12, 2025 | marketbeat.comInsider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Sells 175,000 Shares of StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) Director Daniel Lynch sold 175,000 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $54.46, for a total transaction of $9,530,500.00. Following the completion of the transaction, the director now owns 130,944 shares of the company's stock, valued at approximately $7,131,210.24. This trade represents a 57.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.February 12, 2025 | marketbeat.comSpringWorks shares rise on FDA nod for GOMEKLIFebruary 12, 2025 | msn.comSpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25February 12, 2025 | markets.businessinsider.comSpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up on Analyst UpgradeSpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up After Analyst UpgradeFebruary 12, 2025 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Price Target Raised to $65.00Evercore ISI boosted their target price on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday.February 12, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for SpringWorks Therapeutics (NASDAQ:SWTX)HC Wainwright reiterated a "buy" rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday.February 12, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Springworks Therapeutics (SWTX)February 12, 2025 | markets.businessinsider.comUS FDA approves SpringWorks' genetic disorder drugFebruary 11, 2025 | reuters.comUPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNFebruary 11, 2025 | globenewswire.comSpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNFebruary 11, 2025 | globenewswire.comSmart Money Is Betting Big In SWTX OptionsFebruary 11, 2025 | benzinga.comWhy SpringWorks Therapeutics Inc. (SWTX) Soared on MondayFebruary 11, 2025 | msn.comSpringWorks Therapeutics price target raised to $65 from $55 at BofAFebruary 11, 2025 | markets.businessinsider.comSpringWorks Therapeutics (NASDAQ:SWTX) Hits New 1-Year High - Here's WhySpringWorks Therapeutics (NASDAQ:SWTX) Sets New 52-Week High - Time to Buy?February 11, 2025 | marketbeat.comSpringWorks Therapeutics' (SWTX) Outperform Rating Reiterated at WedbushFebruary 11, 2025 | americanbankingnews.comInvestors Purchase Large Volume of SpringWorks Therapeutics Call Options (NASDAQ:SWTX)February 11, 2025 | americanbankingnews.comWedbush Reiterates "Outperform" Rating for SpringWorks Therapeutics (NASDAQ:SWTX)Wedbush reiterated an "outperform" rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a research note on Monday.February 10, 2025 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Up 31.5% - What's Next?SpringWorks Therapeutics (NASDAQ:SWTX) Shares Up 31.5% - Still a Buy?February 10, 2025 | marketbeat.comTop Growth Stocks To Follow Today - February 10thSpringWorks Therapeutics, Novo Nordisk A/S, BlackRock, Blackstone, and Incyte are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies that are expected to grow at a faster rate than the average for the market or industry. TheseFebruary 10, 2025 | marketbeat.comSpringWorks Therapeutics Shares Rise on Report it May be AcquiredFebruary 10, 2025 | marketwatch.comExclusive-Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources sayFebruary 10, 2025 | investing.com Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address SWTX Media Mentions By Week SWTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SWTX News Sentiment▼0.170.60▲Average Medical News Sentiment SWTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SWTX Articles This Week▼275▲SWTX Articles Average Week Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Genmab A/S News Today Intra-Cellular Therapies News Today Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Sarepta Therapeutics News Today Qiagen News Today Ascendis Pharma A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SWTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
